BRISTOL-MYERS SQUIBB COMPANY Current Income Tax Expense (Benefit)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Current Income Tax Expense (Benefit) of $3.24 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY current income tax expense (benefit) for the quarter ending 2014-06-30 was -$15.00M.
- BRISTOL-MYERS SQUIBB COMPANY current income tax expense (benefit) for the quarter ending 2014-03-31 was $96.00M.
- BRISTOL-MYERS SQUIBB COMPANY current income tax expense (benefit) for fiscal 2025 was $3.24B, a 22.47% increase from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY current income tax expense (benefit) for fiscal 2024 was $2.64B, a 28.34% decline from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY current income tax expense (benefit) for fiscal 2023 was $3.69B, a 10.18% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY current income tax expense (benefit) for fiscal 2022 was $4.11B, a 65.77% increase from fiscal 2021.
| Period end | Current Income Tax Expense (Benefit) 3 month | Current Income Tax Expense (Benefit) 6 month | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | $3.24B 10-K · filed 2026-02-11 | |||
| 2024-12-31 | $2.64B 10-K · filed 2026-02-11 | |||
| 2023-12-31 | $3.69B 10-K · filed 2026-02-11 | |||
| 2022-12-31 | $4.11B 10-K · filed 2025-02-12 | |||
| 2021-12-31 | $2.48B 10-K · filed 2024-02-13 | |||
| 2020-12-31 | $1.14B 10-K · filed 2023-02-14 | |||
| 2019-12-31 | $2.44B 10-K · filed 2022-02-09 | |||
| 2018-12-31 | $976.00M 10-K · filed 2021-02-10 | $935.00M 10-K · filed 2019-02-25 | ||
| 2017-12-31 | $3.70B 10-K · filed 2020-02-24 | $3.15B 10-K · filed 2018-02-13 | ||
| 2016-12-31 | $1.61B 10-K · filed 2019-02-25 | |||
| 2015-12-31 | $793.00M 10-K · filed 2018-02-13 | |||
| 2014-12-31 | $894.00M 10-K · filed 2017-02-21 | |||
| 2014-06-30 | -$15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-23 | $81.00M 10-Q · filed 2015-07-23 | ||
| 2014-03-31 | $96.00M 10-Q · filed 2015-04-28 | |||
| 2013-12-31 | $802.00M 10-K · filed 2016-02-12 | |||
| 2012-12-31 | $1.07B 10-K · filed 2015-02-13 | |||
| 2011-12-31 | $1.31B 10-K · filed 2014-02-14 | |||
| 2010-12-31 | $1.14B 10-K · filed 2013-02-15 | |||
| 2009-12-31 | $1.06B 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |